Michigan GLP-1 Coverage Guide
Michigan has restrictive GLP-1 access for obesity, with Medicaid covering diabetes indications but not weight management. The Healthy Michigan Plan expanded Medicaid eligibility, but anti-obesity medication coverage remains limited.
Medically reviewed by Dr. Sarah Chen, PharmD • Last updated April 2026
Medicaid Status
Medicaid coverage for GLP-1 medications is currently limited in this state.
Medicare Eligibility
Medicare Part D may cover GLP-1 medications for eligible indications.
Coverage Overview
Michigan offers moderate GLP-1 medication access — better than Texas or Florida due to Medicaid expansion under the ACA, but more restrictive than California or New York for obesity-specific treatment. The Healthy Michigan Plan expanded Medicaid to cover adults up to 138% of the Federal Poverty Level, giving approximately 1 million additional residents healthcare coverage. However, Michigan Medicaid does not currently cover GLP-1 medications for weight management alone — a diabetes diagnosis or other approved indication is required for coverage.
Michigan Medicaid (Healthy Michigan Plan)
Michigan Medicaid covers GLP-1 medications for Type 2 diabetes through its managed care plans but does not currently cover anti-obesity medications for weight loss as a standalone indication. Coverage is delivered through managed care organizations:
- Meridian Health Plan — Michigan’s largest Medicaid managed care plan; covers GLP-1s for diabetes with prior authorization
- Molina Healthcare of Michigan — covers semaglutide and tirzepatide for diabetes with step therapy (typically metformin first)
- Blue Cross Complete of Michigan — covers GLP-1s for diabetes; requires PA and documentation of A1C levels
- HAP Midwest Health Plan — covers with prior authorization for diabetes indication
- UnitedHealthcare Community Plan (MI) — covers for diabetes with standard PA requirements
Healthy Michigan Plan eligibility: Adults aged 19–64 earning up to 138% of the Federal Poverty Level ($20,783/year for a single adult in 2026). Michigan’s expansion covers approximately 1 million residents who would otherwise be uninsured. Apply at michigan.gov/healthymichiganplan or call 1-855-789-5610.
For diabetes patients, prior authorization requires documentation of current A1C levels (typically ≥7.0%), failure or intolerance of first-line oral diabetes medications, and clinical rationale for GLP-1 therapy over alternatives.
Commercial Insurance
Michigan’s commercial insurance landscape offers mixed GLP-1 coverage:
- Blue Cross Blue Shield of Michigan — the state’s dominant commercial insurer covers GLP-1s for diabetes universally. Obesity coverage is expanding across large employer plans, particularly in the automotive and manufacturing sectors where employer-sponsored benefits are comprehensive.
- Priority Health — West Michigan’s major insurer; covers for diabetes, expanding obesity coverage in select plans.
- HAP (Health Alliance Plan) — covers for diabetes; obesity coverage varies by employer selection.
- United Healthcare (MI) — standard diabetes coverage; obesity coverage plan-dependent.
- Aetna (MI) — diabetes coverage standard; obesity coverage requires employer plan riders.
Michigan’s large employer base (auto industry, healthcare systems, universities) means many commercial plans offer relatively generous benefits. If you work for a large Michigan employer, check your specific formulary — anti-obesity medication coverage is expanding year over year.
Eligibility Requirements
- Prior authorization is required by all Michigan insurers for GLP-1 medications
- Type 2 diabetes diagnoses have the strongest and most straightforward approval pathway
- Obesity-only coverage typically requires BMI ≥30 (or ≥27 with comorbidities), documented lifestyle modification attempts (3–6 months), and physician letter of medical necessity
- Step therapy may be required: trying metformin or other oral agents before GLP-1 approval for diabetes, or documenting diet/exercise failure for obesity
- Some plans require specialist referral (endocrinologist or obesity medicine specialist) for GLP-1 prescriptions
Appeals Process
Michigan provides standard appeal protections:
- Internal appeal (Grievance): File within 180 days of denial. Insurers must respond within 30 days for standard appeals, 72 hours for urgent/expedited cases.
- External review: If internal appeal is denied, request an external review through the Michigan Department of Insurance and Financial Services (DIFS). File at michigan.gov/difs or call 1-877-999-6442.
- For Medicaid: File a grievance through your managed care plan. If unresolved, you can request a Fair Hearing through the Michigan Office of Administrative Hearings and Rules (MOAHR) at 1-877-833-0870.
- Documentation tips: Include physician letter of medical necessity, BMI and weight trends, comorbidity records (especially cardiovascular risk factors), prior medication trials, and lifestyle modification documentation. For diabetes patients, include A1C history showing inadequate control on current regimen.
Telehealth and Cash-Pay Options
Michigan residents have access to all major telehealth GLP-1 providers:
- Manufacturer programs: NovoCare (Wegovy Pill at $149/month, injectable Wegovy at $349/month), LillyDirect (Zepbound at $299–449/month depending on dose)
- Telehealth platforms: Hims, Ro, Found, Calibrate, Noom Med all operate in Michigan
- Cash-pay compounded options start at $149/month, though availability is reduced following the FDA’s February 2026 regulatory changes
Michigan allows telehealth prescribing for GLP-1 medications via video consultation statewide, including rural Upper Peninsula communities where in-person obesity medicine specialists may not be available.